APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastrointestinal Motility Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gastrointestinal Motility Drugs Market Outlook and Growth Opportunities 2026

27 December 2025210 pages

Choose your research edition.

Industry ResearchGastrointestinal Motility Drugs Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastrointestinal Motility Drugs Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Gastrointestinal Motility Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastrointestinal Motility Drugs Market Outlook and Growth Opportunities 2026210 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastrointestinal Motility Drugs Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global Gastrointestinal Motility Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gastrointestinal Motility Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gastrointestinal Motility Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gastrointestinal Motility Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gastrointestinal Motility Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gastrointestinal Motility Drugs market include Zhuhai Rundu Pharmaceutical Co., Ltd., Yabao Pharmaceutical Group Co., Ltd., Sichuan Zilinggong Pharmaceutical Co., Ltd., Shijiazhuang Siyao Co., Ltd., Shandong Xinhua Pharmaceutical Co., Ltd., Shandong Fangming Pharmaceutical Group Co., Ltd., Lunan Beite Pharmaceutical Co., Ltd., Jiangxi Huiren Pharmaceutical Co., Ltd. and Jiangsu Jibei Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Gastrointestinal Motility Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gastrointestinal Motility Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gastrointestinal Motility Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gastrointestinal Motility Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Gastrointestinal Motility Drugs Segment by Company

Zhuhai Rundu Pharmaceutical Co., Ltd.

Yabao Pharmaceutical Group Co., Ltd.

Sichuan Zilinggong Pharmaceutical Co., Ltd.

Shijiazhuang Siyao Co., Ltd.

Shandong Xinhua Pharmaceutical Co., Ltd.

Shandong Fangming Pharmaceutical Group Co., Ltd.

Lunan Beite Pharmaceutical Co., Ltd.

Jiangxi Huiren Pharmaceutical Co., Ltd.

Jiangsu Jibei Pharmaceutical Co., Ltd.

Jiangsu Hausen Pharmaceutical Group Co., Ltd.

China Resources Double Crane Pharmaceutical Co., Ltd.

Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd.

Hainan Asia Pharmaceutical Co., Ltd.

Guangdong Annuo Pharmaceutical Co., Ltd.

Disa Pharmaceutical Group Co., Ltd.

Chenxin Pharmaceutical Co., Ltd.

Taj Pharmaceuticals Limited

Sumitomo Pharma Co., Ltd.

Pfizer

Midas Pharma GmbH

Janssen Pharmaceutica

Hanmi Pharm. Co., Ltd.

ANI Pharmaceuticals, Inc.

Abbott

Gastrointestinal Motility Drugs Segment by Type

Domperidone

Metoclopramide

Mosapride

Minaprocaine Bromide

Itopride

Gastrointestinal Motility Drugs Segment by Application

Clinic

Hospital

Other

Gastrointestinal Motility Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gastrointestinal Motility Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Gastrointestinal Motility Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gastrointestinal Motility Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Gastrointestinal Motility Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Motility Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Motility Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Motility Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gastrointestinal Motility Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gastrointestinal Motility Drugs industry.

Chapter 3: Detailed analysis of Gastrointestinal Motility Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Gastrointestinal Motility Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Gastrointestinal Motility Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gastrointestinal Motility Drugs Industry Trends Table 2. Gastrointestinal Motility Drugs Industry Drivers Table 3. Gastrointestinal Motility Drugs Industry Opportunities and Challenges Table 4. Gastrointestinal Motility Drugs Industry Restraints Table 5. Global Gastrointestinal Motility Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gastrointestinal Motility Drugs Revenue Share by Company (2021-2026) Table 7. Global Gastrointestinal Motility Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Gastrointestinal Motility Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Gastrointestinal Motility Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Gastrointestinal Motility Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Gastrointestinal Motility Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Gastrointestinal Motility Drugs Company, Product Type & Application Table 13. Global Gastrointestinal Motility Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Gastrointestinal Motility Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Domperidone Table 18. Significant Companies of Metoclopramide Table 19. Significant Companies of Mosapride Table 20. Significant Companies of Minaprocaine Bromide Table 21. Significant Companies of Itopride Table 22. Global Gastrointestinal Motility Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Gastrointestinal Motility Drugs Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Gastrointestinal Motility Drugs Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Gastrointestinal Motility Drugs Sales Volume Share by Type (2021-2026) Table 26. Global Gastrointestinal Motility Drugs Sales Volume Share by Type (2027-2032) Table 27. Global Gastrointestinal Motility Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Gastrointestinal Motility Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Gastrointestinal Motility Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Gastrointestinal Motility Drugs Sales Value Share by Type (2021-2026) Table 31. Global Gastrointestinal Motility Drugs Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Clinic Table 33. Significant Companies of Hospital Table 34. Significant Companies of Other Table 35. Global Gastrointestinal Motility Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Gastrointestinal Motility Drugs Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Gastrointestinal Motility Drugs Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Gastrointestinal Motility Drugs Sales Volume Share by Application (2021-2026) Table 39. Global Gastrointestinal Motility Drugs Sales Volume Share by Application (2027-2032) Table 40. Global Gastrointestinal Motility Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Gastrointestinal Motility Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Gastrointestinal Motility Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Gastrointestinal Motility Drugs Sales Value Share by Application (2021-2026) Table 44. Global Gastrointestinal Motility Drugs Sales Value Share by Application (2027-2032) Table 45. Global Gastrointestinal Motility Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Gastrointestinal Motility Drugs Sales by Region (2021-2026) & (K Units) Table 47. Global Gastrointestinal Motility Drugs Sales Market Share by Region (2021-2026) Table 48. Global Gastrointestinal Motility Drugs Sales by Region (2027-2032) & (K Units) Table 49. Global Gastrointestinal Motility Drugs Sales Market Share by Region (2027-2032) Table 50. Global Gastrointestinal Motility Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Gastrointestinal Motility Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Gastrointestinal Motility Drugs Sales Value Share by Region (2021-2026) Table 53. Global Gastrointestinal Motility Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Gastrointestinal Motility Drugs Sales Value Share by Region (2027-2032) Table 55. Global Gastrointestinal Motility Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Gastrointestinal Motility Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Gastrointestinal Motility Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Gastrointestinal Motility Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Gastrointestinal Motility Drugs Sales by Country (2021-2026) & (K Units) Table 60. Global Gastrointestinal Motility Drugs Sales Market Share by Country (2021-2026) Table 61. Global Gastrointestinal Motility Drugs Sales by Country (2027-2032) & (K Units) Table 62. Global Gastrointestinal Motility Drugs Sales Market Share by Country (2027-2032) Table 63. Global Gastrointestinal Motility Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Gastrointestinal Motility Drugs Sales Value Market Share by Country (2021-2026) Table 65. Global Gastrointestinal Motility Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Gastrointestinal Motility Drugs Sales Value Market Share by Country (2027-2032) Table 67. Zhuhai Rundu Pharmaceutical Co., Ltd. Company Information Table 68. Zhuhai Rundu Pharmaceutical Co., Ltd. Business Overview Table 69. Zhuhai Rundu Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Zhuhai Rundu Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 71. Zhuhai Rundu Pharmaceutical Co., Ltd. Recent Development Table 72. Yabao Pharmaceutical Group Co., Ltd. Company Information Table 73. Yabao Pharmaceutical Group Co., Ltd. Business Overview Table 74. Yabao Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Yabao Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 76. Yabao Pharmaceutical Group Co., Ltd. Recent Development Table 77. Sichuan Zilinggong Pharmaceutical Co., Ltd. Company Information Table 78. Sichuan Zilinggong Pharmaceutical Co., Ltd. Business Overview Table 79. Sichuan Zilinggong Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Sichuan Zilinggong Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 81. Sichuan Zilinggong Pharmaceutical Co., Ltd. Recent Development Table 82. Shijiazhuang Siyao Co., Ltd. Company Information Table 83. Shijiazhuang Siyao Co., Ltd. Business Overview Table 84. Shijiazhuang Siyao Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Shijiazhuang Siyao Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 86. Shijiazhuang Siyao Co., Ltd. Recent Development Table 87. Shandong Xinhua Pharmaceutical Co., Ltd. Company Information Table 88. Shandong Xinhua Pharmaceutical Co., Ltd. Business Overview Table 89. Shandong Xinhua Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Shandong Xinhua Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 91. Shandong Xinhua Pharmaceutical Co., Ltd. Recent Development Table 92. Shandong Fangming Pharmaceutical Group Co., Ltd. Company Information Table 93. Shandong Fangming Pharmaceutical Group Co., Ltd. Business Overview Table 94. Shandong Fangming Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Shandong Fangming Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 96. Shandong Fangming Pharmaceutical Group Co., Ltd. Recent Development Table 97. Lunan Beite Pharmaceutical Co., Ltd. Company Information Table 98. Lunan Beite Pharmaceutical Co., Ltd. Business Overview Table 99. Lunan Beite Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Lunan Beite Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 101. Lunan Beite Pharmaceutical Co., Ltd. Recent Development Table 102. Jiangxi Huiren Pharmaceutical Co., Ltd. Company Information Table 103. Jiangxi Huiren Pharmaceutical Co., Ltd. Business Overview Table 104. Jiangxi Huiren Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Jiangxi Huiren Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 106. Jiangxi Huiren Pharmaceutical Co., Ltd. Recent Development Table 107. Jiangsu Jibei Pharmaceutical Co., Ltd. Company Information Table 108. Jiangsu Jibei Pharmaceutical Co., Ltd. Business Overview Table 109. Jiangsu Jibei Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Jiangsu Jibei Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 111. Jiangsu Jibei Pharmaceutical Co., Ltd. Recent Development Table 112. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Company Information Table 113. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Business Overview Table 114. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 116. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Recent Development Table 117. China Resources Double Crane Pharmaceutical Co., Ltd. Company Information Table 118. China Resources Double Crane Pharmaceutical Co., Ltd. Business Overview Table 119. China Resources Double Crane Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. China Resources Double Crane Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 121. China Resources Double Crane Pharmaceutical Co., Ltd. Recent Development Table 122. Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Company Information Table 123. Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Business Overview Table 124. Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 126. Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Recent Development Table 127. Hainan Asia Pharmaceutical Co., Ltd. Company Information Table 128. Hainan Asia Pharmaceutical Co., Ltd. Business Overview Table 129. Hainan Asia Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Hainan Asia Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 131. Hainan Asia Pharmaceutical Co., Ltd. Recent Development Table 132. Guangdong Annuo Pharmaceutical Co., Ltd. Company Information Table 133. Guangdong Annuo Pharmaceutical Co., Ltd. Business Overview Table 134. Guangdong Annuo Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Guangdong Annuo Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 136. Guangdong Annuo Pharmaceutical Co., Ltd. Recent Development Table 137. Disa Pharmaceutical Group Co., Ltd. Company Information Table 138. Disa Pharmaceutical Group Co., Ltd. Business Overview Table 139. Disa Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Disa Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 141. Disa Pharmaceutical Group Co., Ltd. Recent Development Table 142. Chenxin Pharmaceutical Co., Ltd. Company Information Table 143. Chenxin Pharmaceutical Co., Ltd. Business Overview Table 144. Chenxin Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Chenxin Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 146. Chenxin Pharmaceutical Co., Ltd. Recent Development Table 147. Taj Pharmaceuticals Limited Company Information Table 148. Taj Pharmaceuticals Limited Business Overview Table 149. Taj Pharmaceuticals Limited Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Taj Pharmaceuticals Limited Gastrointestinal Motility Drugs Product Portfolio Table 151. Taj Pharmaceuticals Limited Recent Development Table 152. Sumitomo Pharma Co., Ltd. Company Information Table 153. Sumitomo Pharma Co., Ltd. Business Overview Table 154. Sumitomo Pharma Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Sumitomo Pharma Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 156. Sumitomo Pharma Co., Ltd. Recent Development Table 157. Pfizer Company Information Table 158. Pfizer Business Overview Table 159. Pfizer Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Pfizer Gastrointestinal Motility Drugs Product Portfolio Table 161. Pfizer Recent Development Table 162. Midas Pharma GmbH Company Information Table 163. Midas Pharma GmbH Business Overview Table 164. Midas Pharma GmbH Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Midas Pharma GmbH Gastrointestinal Motility Drugs Product Portfolio Table 166. Midas Pharma GmbH Recent Development Table 167. Janssen Pharmaceutica Company Information Table 168. Janssen Pharmaceutica Business Overview Table 169. Janssen Pharmaceutica Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 170. Janssen Pharmaceutica Gastrointestinal Motility Drugs Product Portfolio Table 171. Janssen Pharmaceutica Recent Development Table 172. Hanmi Pharm. Co., Ltd. Company Information Table 173. Hanmi Pharm. Co., Ltd. Business Overview Table 174. Hanmi Pharm. Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 175. Hanmi Pharm. Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 176. Hanmi Pharm. Co., Ltd. Recent Development Table 177. ANI Pharmaceuticals, Inc. Company Information Table 178. ANI Pharmaceuticals, Inc. Business Overview Table 179. ANI Pharmaceuticals, Inc. Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 180. ANI Pharmaceuticals, Inc. Gastrointestinal Motility Drugs Product Portfolio Table 181. ANI Pharmaceuticals, Inc. Recent Development Table 182. Abbott Company Information Table 183. Abbott Business Overview Table 184. Abbott Gastrointestinal Motility Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 185. Abbott Gastrointestinal Motility Drugs Product Portfolio Table 186. Abbott Recent Development Table 187. Key Raw Materials Table 188. Raw Materials Key Suppliers Table 189. Gastrointestinal Motility Drugs Distributors List Table 190. Gastrointestinal Motility Drugs Customers List Table 191. Research Programs/Design for This Report Table 192. Authors List of This Report Table 193. Secondary Sources Table 194. Primary Sources List of Figures Figure 1. Gastrointestinal Motility Drugs Product Image Figure 2. Global Gastrointestinal Motility Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastrointestinal Motility Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Gastrointestinal Motility Drugs Sales (2021-2032) & (K Units) Figure 5. Global Gastrointestinal Motility Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Gastrointestinal Motility Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Domperidone Image Figure 10. Metoclopramide Image Figure 11. Mosapride Image Figure 12. Minaprocaine Bromide Image Figure 13. Itopride Image Figure 14. Global Gastrointestinal Motility Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Gastrointestinal Motility Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Gastrointestinal Motility Drugs Sales Volume Share by Type (2021-2032) Figure 17. Global Gastrointestinal Motility Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Gastrointestinal Motility Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Gastrointestinal Motility Drugs Sales Value Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Other Image Figure 23. Global Gastrointestinal Motility Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Gastrointestinal Motility Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Gastrointestinal Motility Drugs Sales Volume Share by Application (2021-2032) Figure 26. Global Gastrointestinal Motility Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Gastrointestinal Motility Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Gastrointestinal Motility Drugs Sales Value Share by Application (2021-2032) Figure 29. Global Gastrointestinal Motility Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Gastrointestinal Motility Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Gastrointestinal Motility Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Gastrointestinal Motility Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Gastrointestinal Motility Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. North America Gastrointestinal Motility Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Gastrointestinal Motility Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Gastrointestinal Motility Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Gastrointestinal Motility Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Gastrointestinal Motility Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Gastrointestinal Motility Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. South America Gastrointestinal Motility Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Gastrointestinal Motility Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Gastrointestinal Motility Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Gastrointestinal Motility Drugs Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Gastrointestinal Motility Drugs Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Domperidone
  • Metoclopramide
  • Mosapride
  • Minaprocaine Bromide
  • Itopride
Applications
  • Clinic
  • Hospital
  • Other
Companies covered
  • Zhuhai Rundu Pharmaceutical Co., Ltd.
  • Yabao Pharmaceutical Group Co., Ltd.
  • Sichuan Zilinggong Pharmaceutical Co., Ltd.
  • Shijiazhuang Siyao Co., Ltd.
  • Shandong Xinhua Pharmaceutical Co., Ltd.
  • Shandong Fangming Pharmaceutical Group Co., Ltd.
  • Lunan Beite Pharmaceutical Co., Ltd.
  • Jiangxi Huiren Pharmaceutical Co., Ltd.
  • Jiangsu Jibei Pharmaceutical Co., Ltd.
  • Jiangsu Hausen Pharmaceutical Group Co., Ltd.
  • China Resources Double Crane Pharmaceutical Co., Ltd.
  • Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd.
  • Hainan Asia Pharmaceutical Co., Ltd.
  • Guangdong Annuo Pharmaceutical Co., Ltd.
  • Disa Pharmaceutical Group Co., Ltd.
  • Chenxin Pharmaceutical Co., Ltd.
  • Taj Pharmaceuticals Limited
  • Sumitomo Pharma Co., Ltd.
  • Pfizer
  • Midas Pharma GmbH
  • Janssen Pharmaceutica
  • Hanmi Pharm. Co., Ltd.
  • ANI Pharmaceuticals, Inc.
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Gastrointestinal Motility Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Gastrointestinal Motility Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Gastrointestinal Motility Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Gastrointestinal Motility Drugs Market Dynamics
  1. 2.1 Gastrointestinal Motility Drugs Industry Trends
  2. 2.2 Gastrointestinal Motility Drugs Industry Drivers
  3. 2.3 Gastrointestinal Motility Drugs Industry Opportunities and Challenges
  4. 2.4 Gastrointestinal Motility Drugs Industry Restraints
3 Gastrointestinal Motility Drugs Market by Company
  1. 3.1 Global Gastrointestinal Motility Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Gastrointestinal Motility Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Gastrointestinal Motility Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Gastrointestinal Motility Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Gastrointestinal Motility Drugs Company Ranking (2024-2026)
  6. 3.6 Global Gastrointestinal Motility Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Gastrointestinal Motility Drugs Company Product Type and Application
  8. 3.8 Global Gastrointestinal Motility Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Gastrointestinal Motility Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Gastrointestinal Motility Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Gastrointestinal Motility Drugs Market by Type
  1. 4.1 Gastrointestinal Motility Drugs Type Introduction
  2. 4.1.1 Domperidone
  3. 4.1.2 Metoclopramide
  4. 4.1.3 Mosapride
  5. 4.1.4 Minaprocaine Bromide
  6. 4.1.5 Itopride
  7. 4.2 Global Gastrointestinal Motility Drugs Sales Volume by Type
  8. 4.2.1 Global Gastrointestinal Motility Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Gastrointestinal Motility Drugs Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Gastrointestinal Motility Drugs Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Gastrointestinal Motility Drugs Sales Value by Type
  12. 4.3.1 Global Gastrointestinal Motility Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Gastrointestinal Motility Drugs Sales Value by Type (2021-2032)
  14. 4.3.3 Global Gastrointestinal Motility Drugs Sales Value Share by Type (2021-2032)
5 Gastrointestinal Motility Drugs Market by Application
  1. 5.1 Gastrointestinal Motility Drugs Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Other
  5. 5.2 Global Gastrointestinal Motility Drugs Sales Volume by Application
  6. 5.2.1 Global Gastrointestinal Motility Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Gastrointestinal Motility Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Gastrointestinal Motility Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Gastrointestinal Motility Drugs Sales Value by Application
  10. 5.3.1 Global Gastrointestinal Motility Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Gastrointestinal Motility Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Gastrointestinal Motility Drugs Sales Value Share by Application (2021-2032)
6 Gastrointestinal Motility Drugs Regional Sales and Value Analysis
  1. 6.1 Global Gastrointestinal Motility Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gastrointestinal Motility Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Gastrointestinal Motility Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Gastrointestinal Motility Drugs Sales by Region (2027-2032)
  5. 6.3 Global Gastrointestinal Motility Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Gastrointestinal Motility Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Gastrointestinal Motility Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Gastrointestinal Motility Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Gastrointestinal Motility Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Gastrointestinal Motility Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Gastrointestinal Motility Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Gastrointestinal Motility Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Gastrointestinal Motility Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Gastrointestinal Motility Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Gastrointestinal Motility Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Gastrointestinal Motility Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Gastrointestinal Motility Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Gastrointestinal Motility Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Gastrointestinal Motility Drugs Sales Value Share by Country, 2025 VS 2032
7 Gastrointestinal Motility Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Gastrointestinal Motility Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gastrointestinal Motility Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Gastrointestinal Motility Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Gastrointestinal Motility Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Gastrointestinal Motility Drugs Sales by Country (2027-2032)
  6. 7.4 Global Gastrointestinal Motility Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Gastrointestinal Motility Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Gastrointestinal Motility Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Gastrointestinal Motility Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Gastrointestinal Motility Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Gastrointestinal Motility Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhuhai Rundu Pharmaceutical Co., Ltd.
  2. 8.1.1 Zhuhai Rundu Pharmaceutical Co., Ltd. Company Information
  3. 8.1.2 Zhuhai Rundu Pharmaceutical Co., Ltd. Business Overview
  4. 8.1.3 Zhuhai Rundu Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Zhuhai Rundu Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  6. 8.1.5 Zhuhai Rundu Pharmaceutical Co., Ltd. Recent Developments
  7. 8.2 Yabao Pharmaceutical Group Co., Ltd.
  8. 8.2.1 Yabao Pharmaceutical Group Co., Ltd. Company Information
  9. 8.2.2 Yabao Pharmaceutical Group Co., Ltd. Business Overview
  10. 8.2.3 Yabao Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Yabao Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  12. 8.2.5 Yabao Pharmaceutical Group Co., Ltd. Recent Developments
  13. 8.3 Sichuan Zilinggong Pharmaceutical Co., Ltd.
  14. 8.3.1 Sichuan Zilinggong Pharmaceutical Co., Ltd. Company Information
  15. 8.3.2 Sichuan Zilinggong Pharmaceutical Co., Ltd. Business Overview
  16. 8.3.3 Sichuan Zilinggong Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sichuan Zilinggong Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  18. 8.3.5 Sichuan Zilinggong Pharmaceutical Co., Ltd. Recent Developments
  19. 8.4 Shijiazhuang Siyao Co., Ltd.
  20. 8.4.1 Shijiazhuang Siyao Co., Ltd. Company Information
  21. 8.4.2 Shijiazhuang Siyao Co., Ltd. Business Overview
  22. 8.4.3 Shijiazhuang Siyao Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Shijiazhuang Siyao Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  24. 8.4.5 Shijiazhuang Siyao Co., Ltd. Recent Developments
  25. 8.5 Shandong Xinhua Pharmaceutical Co., Ltd.
  26. 8.5.1 Shandong Xinhua Pharmaceutical Co., Ltd. Company Information
  27. 8.5.2 Shandong Xinhua Pharmaceutical Co., Ltd. Business Overview
  28. 8.5.3 Shandong Xinhua Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Shandong Xinhua Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  30. 8.5.5 Shandong Xinhua Pharmaceutical Co., Ltd. Recent Developments
  31. 8.6 Shandong Fangming Pharmaceutical Group Co., Ltd.
  32. 8.6.1 Shandong Fangming Pharmaceutical Group Co., Ltd. Company Information
  33. 8.6.2 Shandong Fangming Pharmaceutical Group Co., Ltd. Business Overview
  34. 8.6.3 Shandong Fangming Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Shandong Fangming Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  36. 8.6.5 Shandong Fangming Pharmaceutical Group Co., Ltd. Recent Developments
  37. 8.7 Lunan Beite Pharmaceutical Co., Ltd.
  38. 8.7.1 Lunan Beite Pharmaceutical Co., Ltd. Company Information
  39. 8.7.2 Lunan Beite Pharmaceutical Co., Ltd. Business Overview
  40. 8.7.3 Lunan Beite Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Lunan Beite Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  42. 8.7.5 Lunan Beite Pharmaceutical Co., Ltd. Recent Developments
  43. 8.8 Jiangxi Huiren Pharmaceutical Co., Ltd.
  44. 8.8.1 Jiangxi Huiren Pharmaceutical Co., Ltd. Company Information
  45. 8.8.2 Jiangxi Huiren Pharmaceutical Co., Ltd. Business Overview
  46. 8.8.3 Jiangxi Huiren Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Jiangxi Huiren Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  48. 8.8.5 Jiangxi Huiren Pharmaceutical Co., Ltd. Recent Developments
  49. 8.9 Jiangsu Jibei Pharmaceutical Co., Ltd.
  50. 8.9.1 Jiangsu Jibei Pharmaceutical Co., Ltd. Company Information
  51. 8.9.2 Jiangsu Jibei Pharmaceutical Co., Ltd. Business Overview
  52. 8.9.3 Jiangsu Jibei Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Jibei Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  54. 8.9.5 Jiangsu Jibei Pharmaceutical Co., Ltd. Recent Developments
  55. 8.10 Jiangsu Hausen Pharmaceutical Group Co., Ltd.
  56. 8.10.1 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Company Information
  57. 8.10.2 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Business Overview
  58. 8.10.3 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  60. 8.10.5 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Recent Developments
  61. 8.11 China Resources Double Crane Pharmaceutical Co., Ltd.
  62. 8.11.1 China Resources Double Crane Pharmaceutical Co., Ltd. Company Information
  63. 8.11.2 China Resources Double Crane Pharmaceutical Co., Ltd. Business Overview
  64. 8.11.3 China Resources Double Crane Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 China Resources Double Crane Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  66. 8.11.5 China Resources Double Crane Pharmaceutical Co., Ltd. Recent Developments
  67. 8.12 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd.
  68. 8.12.1 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Company Information
  69. 8.12.2 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Business Overview
  70. 8.12.3 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  72. 8.12.5 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Recent Developments
  73. 8.13 Hainan Asia Pharmaceutical Co., Ltd.
  74. 8.13.1 Hainan Asia Pharmaceutical Co., Ltd. Company Information
  75. 8.13.2 Hainan Asia Pharmaceutical Co., Ltd. Business Overview
  76. 8.13.3 Hainan Asia Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Hainan Asia Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  78. 8.13.5 Hainan Asia Pharmaceutical Co., Ltd. Recent Developments
  79. 8.14 Guangdong Annuo Pharmaceutical Co., Ltd.
  80. 8.14.1 Guangdong Annuo Pharmaceutical Co., Ltd. Company Information
  81. 8.14.2 Guangdong Annuo Pharmaceutical Co., Ltd. Business Overview
  82. 8.14.3 Guangdong Annuo Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Guangdong Annuo Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  84. 8.14.5 Guangdong Annuo Pharmaceutical Co., Ltd. Recent Developments
  85. 8.15 Disa Pharmaceutical Group Co., Ltd.
  86. 8.15.1 Disa Pharmaceutical Group Co., Ltd. Company Information
  87. 8.15.2 Disa Pharmaceutical Group Co., Ltd. Business Overview
  88. 8.15.3 Disa Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Disa Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  90. 8.15.5 Disa Pharmaceutical Group Co., Ltd. Recent Developments
  91. 8.16 Chenxin Pharmaceutical Co., Ltd.
  92. 8.16.1 Chenxin Pharmaceutical Co., Ltd. Company Information
  93. 8.16.2 Chenxin Pharmaceutical Co., Ltd. Business Overview
  94. 8.16.3 Chenxin Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Chenxin Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  96. 8.16.5 Chenxin Pharmaceutical Co., Ltd. Recent Developments
  97. 8.17 Taj Pharmaceuticals Limited
  98. 8.17.1 Taj Pharmaceuticals Limited Company Information
  99. 8.17.2 Taj Pharmaceuticals Limited Business Overview
  100. 8.17.3 Taj Pharmaceuticals Limited Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Taj Pharmaceuticals Limited Gastrointestinal Motility Drugs Product Portfolio
  102. 8.17.5 Taj Pharmaceuticals Limited Recent Developments
  103. 8.18 Sumitomo Pharma Co., Ltd.
  104. 8.18.1 Sumitomo Pharma Co., Ltd. Company Information
  105. 8.18.2 Sumitomo Pharma Co., Ltd. Business Overview
  106. 8.18.3 Sumitomo Pharma Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Sumitomo Pharma Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  108. 8.18.5 Sumitomo Pharma Co., Ltd. Recent Developments
  109. 8.19 Pfizer
  110. 8.19.1 Pfizer Company Information
  111. 8.19.2 Pfizer Business Overview
  112. 8.19.3 Pfizer Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Pfizer Gastrointestinal Motility Drugs Product Portfolio
  114. 8.19.5 Pfizer Recent Developments
  115. 8.20 Midas Pharma GmbH
  116. 8.20.1 Midas Pharma GmbH Company Information
  117. 8.20.2 Midas Pharma GmbH Business Overview
  118. 8.20.3 Midas Pharma GmbH Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Midas Pharma GmbH Gastrointestinal Motility Drugs Product Portfolio
  120. 8.20.5 Midas Pharma GmbH Recent Developments
  121. 8.21 Janssen Pharmaceutica
  122. 8.21.1 Janssen Pharmaceutica Company Information
  123. 8.21.2 Janssen Pharmaceutica Business Overview
  124. 8.21.3 Janssen Pharmaceutica Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Janssen Pharmaceutica Gastrointestinal Motility Drugs Product Portfolio
  126. 8.21.5 Janssen Pharmaceutica Recent Developments
  127. 8.22 Hanmi Pharm. Co., Ltd.
  128. 8.22.1 Hanmi Pharm. Co., Ltd. Company Information
  129. 8.22.2 Hanmi Pharm. Co., Ltd. Business Overview
  130. 8.22.3 Hanmi Pharm. Co., Ltd. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Hanmi Pharm. Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  132. 8.22.5 Hanmi Pharm. Co., Ltd. Recent Developments
  133. 8.23 ANI Pharmaceuticals, Inc.
  134. 8.23.1 ANI Pharmaceuticals, Inc. Company Information
  135. 8.23.2 ANI Pharmaceuticals, Inc. Business Overview
  136. 8.23.3 ANI Pharmaceuticals, Inc. Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 ANI Pharmaceuticals, Inc. Gastrointestinal Motility Drugs Product Portfolio
  138. 8.23.5 ANI Pharmaceuticals, Inc. Recent Developments
  139. 8.24 Abbott
  140. 8.24.1 Abbott Company Information
  141. 8.24.2 Abbott Business Overview
  142. 8.24.3 Abbott Gastrointestinal Motility Drugs Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Abbott Gastrointestinal Motility Drugs Product Portfolio
  144. 8.24.5 Abbott Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gastrointestinal Motility Drugs Value Chain Analysis
  2. 9.1.1 Gastrointestinal Motility Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gastrointestinal Motility Drugs Sales Mode & Process
  6. 9.2 Gastrointestinal Motility Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gastrointestinal Motility Drugs Distributors
  9. 9.2.3 Gastrointestinal Motility Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst